A detailed history of Ameriprise Financial Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 213,980 shares of SAGE stock, worth $1.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
213,980
Previous 274,649 22.09%
Holding current value
$1.16 Million
Previous $2.98 Million 48.29%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.02 - $13.08 $425,896 - $793,550
-60,669 Reduced 22.09%
213,980 $1.54 Million
Q2 2024

Aug 14, 2024

SELL
$10.58 - $17.9 $898,093 - $1.52 Million
-84,886 Reduced 23.61%
274,649 $2.98 Million
Q1 2024

May 15, 2024

BUY
$18.62 - $26.95 $945,896 - $1.37 Million
50,800 Added 16.45%
359,535 $6.74 Million
Q4 2023

Feb 14, 2024

SELL
$17.1 - $22.26 $6.9 Million - $8.99 Million
-403,689 Reduced 56.66%
308,735 $6.69 Million
Q3 2023

Nov 14, 2023

SELL
$16.75 - $48.98 $2.98 Million - $8.7 Million
-177,619 Reduced 19.96%
712,424 $14.7 Million
Q2 2023

Aug 14, 2023

SELL
$40.65 - $59.54 $9.54 Million - $14 Million
-234,775 Reduced 20.87%
890,043 $41.8 Million
Q1 2023

May 15, 2023

BUY
$37.27 - $46.57 $1.56 Million - $1.95 Million
41,774 Added 3.86%
1,124,818 $47.2 Million
Q4 2022

Feb 14, 2023

SELL
$32.2 - $43.61 $335,942 - $454,983
-10,433 Reduced 0.95%
1,083,044 $41.3 Million
Q3 2022

Nov 14, 2022

BUY
$32.28 - $43.27 $10.4 Million - $13.9 Million
321,121 Added 41.58%
1,093,477 $42.8 Million
Q2 2022

Aug 15, 2022

SELL
$27.52 - $37.99 $1.19 Million - $1.64 Million
-43,265 Reduced 5.3%
772,356 $24.9 Million
Q1 2022

May 16, 2022

BUY
$30.71 - $45.71 $1.15 Million - $1.7 Million
37,299 Added 4.79%
815,621 $27 Million
Q4 2021

Feb 14, 2022

BUY
$37.06 - $47.11 $3.38 Million - $4.3 Million
91,290 Added 13.29%
778,322 $33.1 Million
Q3 2021

Nov 15, 2021

BUY
$40.26 - $57.37 $3.3 Million - $4.71 Million
82,091 Added 13.57%
687,032 $30.4 Million
Q2 2021

Aug 16, 2021

BUY
$54.88 - $79.29 $8.67 Million - $12.5 Million
157,987 Added 35.35%
604,941 $34.4 Million
Q1 2021

May 17, 2021

BUY
$70.65 - $96.76 $4.05 Million - $5.55 Million
57,320 Added 14.71%
446,954 $33.5 Million
Q4 2020

Feb 12, 2021

SELL
$58.41 - $89.06 $21,144 - $32,239
-362 Reduced 0.09%
389,634 $33.7 Million
Q3 2020

Nov 16, 2020

BUY
$41.13 - $62.45 $714,839 - $1.09 Million
17,380 Added 4.66%
389,996 $23.8 Million
Q2 2020

Aug 14, 2020

SELL
$25.95 - $43.15 $6.13 Million - $10.2 Million
-236,098 Reduced 38.79%
372,616 $15.5 Million
Q1 2020

May 15, 2020

BUY
$26.15 - $77.24 $7.03 Million - $20.8 Million
268,789 Added 79.07%
608,714 $17.4 Million
Q4 2019

Feb 14, 2020

SELL
$60.18 - $154.77 $6.92 Million - $17.8 Million
-114,910 Reduced 25.26%
339,925 $24.5 Million
Q3 2019

Nov 14, 2019

SELL
$140.29 - $189.96 $1.37 Million - $1.86 Million
-9,788 Reduced 2.11%
454,835 $63.8 Million
Q2 2019

Aug 14, 2019

BUY
$157.85 - $183.09 $16.9 Million - $19.6 Million
107,140 Added 29.97%
464,623 $85.1 Million
Q1 2019

May 15, 2019

BUY
$89.33 - $163.65 $9.44 Million - $17.3 Million
105,729 Added 42.0%
357,483 $56.9 Million
Q4 2018

Feb 14, 2019

SELL
$81.94 - $139.71 $6.4 Million - $10.9 Million
-78,083 Reduced 23.67%
251,754 $24.1 Million
Q3 2018

Nov 14, 2018

SELL
$138.11 - $169.04 $4.16 Million - $5.09 Million
-30,104 Reduced 8.36%
329,837 $46.3 Million
Q2 2018

Aug 14, 2018

BUY
$140.36 - $175.76 $7.39 Million - $9.25 Million
52,626 Added 17.12%
359,941 $56.3 Million
Q1 2018

May 15, 2018

BUY
$152.15 - $192.33 $19.5 Million - $24.7 Million
128,208 Added 71.58%
307,315 $49.5 Million
Q4 2017

Feb 12, 2018

BUY
$60.72 - $167.34 $7.06 Million - $19.5 Million
116,322 Added 185.27%
179,107 $29.5 Million
Q3 2017

Nov 07, 2017

BUY
$61.4 - $88.52 $3.85 Million - $5.56 Million
62,785
62,785 $3.91 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.